Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Taking Seroquel with methadone can be fatal. Did the drugmaker’s warnings fall short?
“One whiff and you’re stiff.” Residents of Ringaskiddy, Ireland are feeling arousing effects from breathing the air near the local Pfizer plant that manufactures Viagra.
ASIT biotech has received positive feedback from the FDA on the preparation of the clinical development plan for gp-ASIT+ in the U.S., with only a few comments and the request for some clarification on the Master File.
The investigation dates back to a probe launched in May by Israel’s version of the U.S. SEC though the subject matter of the investigation was not initially revealed.
The 3.6mm docking button is designed to allow the Nanostim device to be retrieved after implantation.
The firm failed to submit a report to the agency of a serious injury that may have been caused by one of the company’s medical devices.
Amazon didn’t immediately respond to a request for comment.
According to the report, Isaly made lewd comments to female employees, subjected them to pornographic images and made “pervasive sexist comments.”
Avanir is under fire after CNN filed a report showing how the company paid 500 prescribers about $14M over three years for prescribers to tout the benefits of its leading CNS drug Nuedexta.
The company warns that pumps made before 2008 may display an error message that could stop the pump from working.